Verzenios Unia Europejska - polski - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - nowotwory piersi - Środki przeciwnowotworowe - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Delstrigo Unia Europejska - polski - EMA (European Medicines Agency)

delstrigo

merck sharp & dohme b.v. - doravirine, lamiwudyna, tenofowir disoproxil fumarate - infekcje hiv - leki przeciwwirusowe do leczenia zakażeń hiv, kombinacje - delstrigo jest wskazany w leczeniu osób dorosłych zakażonych hiv-1, bez przeszłych lub aktualnych dowodów opór klasy nnrti, lamiwudyną lub tenofowir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Pifeltro Unia Europejska - polski - EMA (European Medicines Agency)

pifeltro

merck sharp & dohme b.v. - doravirine - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Skysona Unia Europejska - polski - EMA (European Medicines Agency)

skysona

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - inne leki na układ nerwowy - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Evrenzo Unia Europejska - polski - EMA (European Medicines Agency)

evrenzo

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - preparaty antyanemiczne - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Paxlovid Unia Europejska - polski - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Actrapid Unia Europejska - polski - EMA (European Medicines Agency)

actrapid

novo nordisk a/s - insulina ludzka - cukrzyca - leki stosowane w cukrzycy - leczenie cukrzycy.

Ceprotin Unia Europejska - polski - EMA (European Medicines Agency)

ceprotin

takeda manufacturing austria ag - ludzkie białko c - purpura fulminans; protein c deficiency - Środki przeciwzakrzepowe - ceprotin is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.

Coagadex Unia Europejska - polski - EMA (European Medicines Agency)

coagadex

bpl bioproducts laboratory gmbh - ludzki czynnik krzepnięcia x - niedobór czynnika x. - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex jest wskazany w leczeniu i profilaktyce epizodów krwawienia oraz w leczeniu okołooperacyjnym u pacjentów z dziedzicznym niedoborem czynnika x. coagadex wskazuje, we wszystkich grupach wiekowych.

Evarrest Unia Europejska - polski - EMA (European Medicines Agency)

evarrest

omrix biopharmaceuticals n. v. - ludzki fibrynogen, ludzka trombina - hemostaza - miejscowe leki ściągające - leczenie wspomagające w chirurgii u dorosłych, w których standardowe techniki chirurgiczne są niewystarczające (patrz punkt 5). 1):- w celu poprawy hemostazy.